LongR3-IGF-I anti-doping analytical study and product-quality evidence
Authors state LongR3-IGF-I and related analogues were never approved for human use; black-market products showed oxidized/low-quality forms.
What this study tells us
This was analytical or product-characterisation research rather than a treatment trial. It can help establish identity, composition or detectability, but it does not prove a health benefit.
Human serum matrices plus black-market product analysis; animal administration for detectability
No participant count — this was laboratory or analytical research.
Authors state LongR3-IGF-I and related analogues were never approved for human use; black-market products showed oxidized/low-quality forms.
Analytical/detection evidence does not establish efficacy; product-quality findings may not apply to every source but demonstrate real market risk.
Need help with terms such as randomized, placebo, endpoint or sample size? Open the glossary →
Key result
Authors state LongR3-IGF-I and related analogues were never approved for human use; black-market products showed oxidized/low-quality forms.